FI954154A - Gepiroonikoostumuksia - Google Patents

Gepiroonikoostumuksia Download PDF

Info

Publication number
FI954154A
FI954154A FI954154A FI954154A FI954154A FI 954154 A FI954154 A FI 954154A FI 954154 A FI954154 A FI 954154A FI 954154 A FI954154 A FI 954154A FI 954154 A FI954154 A FI 954154A
Authority
FI
Finland
Prior art keywords
colourant
pref
hydroxypropylmethylcellulose
hrs
attain
Prior art date
Application number
FI954154A
Other languages
English (en)
Swedish (sv)
Other versions
FI117319B (fi
FI954154A0 (fi
Inventor
Stephen T David
Claude E Gallian
Joseph C H Chou
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI954154A0 publication Critical patent/FI954154A0/fi
Publication of FI954154A publication Critical patent/FI954154A/fi
Application granted granted Critical
Publication of FI117319B publication Critical patent/FI117319B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Electroluminescent Light Sources (AREA)
FI954154A 1994-09-06 1995-09-05 Gepiroonikoostumuksia FI117319B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30128194 1994-09-06
US08/301,281 US5478572A (en) 1994-09-06 1994-09-06 Gepirone dosage form

Publications (3)

Publication Number Publication Date
FI954154A0 FI954154A0 (fi) 1995-09-05
FI954154A true FI954154A (fi) 1996-03-07
FI117319B FI117319B (fi) 2006-09-15

Family

ID=23162703

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954154A FI117319B (fi) 1994-09-06 1995-09-05 Gepiroonikoostumuksia

Country Status (25)

Country Link
US (1) US5478572A (fi)
EP (1) EP0700680B1 (fi)
JP (1) JP4540756B2 (fi)
KR (1) KR100380806B1 (fi)
CN (1) CN1096858C (fi)
AT (1) ATE186462T1 (fi)
AU (1) AU702282B2 (fi)
CA (1) CA2157323C (fi)
CY (1) CY2222B1 (fi)
CZ (1) CZ286417B6 (fi)
DE (1) DE69513254T2 (fi)
DK (1) DK0700680T3 (fi)
ES (1) ES2142432T3 (fi)
FI (1) FI117319B (fi)
GR (1) GR3032598T3 (fi)
HK (1) HK1014666A1 (fi)
HU (1) HU227339B1 (fi)
IL (1) IL114984A (fi)
NO (1) NO307814B1 (fi)
NZ (1) NZ272855A (fi)
PL (1) PL180691B1 (fi)
RU (1) RU2155044C2 (fi)
SG (1) SG30436A1 (fi)
TW (1) TW445152B (fi)
ZA (1) ZA957144B (fi)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US20060068017A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
CN100367965C (zh) * 1999-12-20 2008-02-13 法布瑞－克雷默制药有限公司 吉吡隆代谢物在制备改善哺乳动物不良心理状态的组合物上的应用
KR20040018314A (ko) * 2000-12-08 2004-03-03 악조 노벨 엔.브이. 게피론을 함유하는 경구 투여용 연장 방출형 제제
KR100568380B1 (ko) 2001-05-01 2006-04-05 화이자 프로덕츠 인코포레이티드 저 투약량 약학 조성물의 제조 방법
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
AU2003274110A1 (en) * 2002-09-24 2004-04-19 Akzo Nobel N.V. Method to improve pharmaceutical tablets having a matrix of cellulose ether
CA2524300C (en) 2003-08-08 2008-10-28 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
AR048112A1 (es) * 2004-03-25 2006-03-29 Solvay Pharm Bv Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor
AR049478A1 (es) * 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US20060013874A1 (en) * 2004-07-15 2006-01-19 Solvay Pharmaceuticals B.V. Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
JP2008506668A (ja) * 2004-07-15 2008-03-06 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ３−アミノ−８−（１−ピペラジニル）−２ｈ−１−ベンゾピラン−２−オンの長時間放出型調製物
MX2007005368A (es) * 2004-11-05 2007-09-11 Fabre Kramer Holdings Inc Formulacion con liberacion prolongada de dosis alta de gepirona.
US20060099267A1 (en) * 2004-11-05 2006-05-11 Fabre-Kramer Pharmaceuticals, Inc. High-dosage extended-release formulation of gepirone
US20090131383A1 (en) * 2005-06-09 2009-05-21 Woodward Richard M Pharmaceutical compositions of a neuroactive steriod and methods of use thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4248858A (en) * 1979-08-09 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US4690824A (en) * 1983-07-07 1987-09-01 Redi-Rowell, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US4782060A (en) * 1987-07-29 1988-11-01 Bristol-Myers Company Gepirone for alleviation of panic disorders
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
SE8704097D0 (sv) * 1987-10-22 1987-10-22 Astra Ab Oral formulation of buspirone and salts thereof
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5124346A (en) * 1991-04-23 1992-06-23 Pfizer Inc. Synergistic combinations in the treatment of anxiety
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5292766A (en) * 1992-03-25 1994-03-08 Eli Lilly And Company Method for improving primary memory and/or learning
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
NZ272855A (en) 1997-05-26
ZA957144B (en) 1996-03-26
NO307814B1 (no) 2000-06-05
SG30436A1 (en) 1996-06-01
IL114984A (en) 1999-10-28
PL180691B1 (en) 2001-03-30
DE69513254T2 (de) 2000-06-15
NO953212D0 (no) 1995-08-16
JP4540756B2 (ja) 2010-09-08
GR3032598T3 (en) 2000-05-31
IL114984A0 (en) 1995-12-08
DK0700680T3 (da) 2000-05-01
FI117319B (fi) 2006-09-15
TW445152B (en) 2001-07-11
KR100380806B1 (ko) 2003-07-10
AU702282B2 (en) 1999-02-18
CA2157323C (en) 2004-01-20
DE69513254D1 (de) 1999-12-16
HK1014666A1 (en) 1999-09-30
HU9502599D0 (en) 1995-11-28
FI954154A0 (fi) 1995-09-05
ES2142432T3 (es) 2000-04-16
CN1096858C (zh) 2002-12-25
ATE186462T1 (de) 1999-11-15
NO953212L (no) 1996-03-07
JPH08183736A (ja) 1996-07-16
HUT73182A (en) 1996-06-28
CA2157323A1 (en) 1996-03-07
US5478572A (en) 1995-12-26
KR960010007A (ko) 1996-04-20
PL310298A1 (en) 1996-03-18
RU2155044C2 (ru) 2000-08-27
CN1128142A (zh) 1996-08-07
EP0700680A1 (en) 1996-03-13
EP0700680B1 (en) 1999-11-10
AU3043895A (en) 1996-03-21
CZ227595A3 (en) 1996-03-13
HU227339B1 (en) 2011-04-28
CY2222B1 (en) 2003-04-18
CZ286417B6 (en) 2000-04-12

Similar Documents

Publication Publication Date Title
FI954154A0 (fi) Gepiroonikoostumuksia
NO20065390L (no) Farmasoytisk preparat i fast enhetsdoseringsform
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
AU646399B2 (en) Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
HUP0202461A2 (hu) Gyógyászati készítmények és azok agyvérzés, diabetes és/vagy elzáródásos szívbénulás megelőzésében történő alkalmazása
DK0501985T3 (da) Uovertrukket farmaceutisk reaktionstablet
AR016827A1 (es) PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
HUT62467A (en) Process for producing locally applicable pharmaceutical compositions comprising allylamine derivative, against fungus infection of nails
HUT62466A (en) Process for producing locally applicable pharmaceutical compositions comprising allylamine derivatives, against fungus infection
NO20004208D0 (no) Fornettet stivelse med høyt amyloseinnhold og med funksjonelle grupper som en matriks for frigivning av farmasøytiske midler
WO1996026718A3 (en) Controlled release tablet
EA200001201A3 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
AU2793989A (en) Method for preparing a solid sustained release form of a functionally active composition and the dosage form so obtained
IL145755A0 (en) Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
GR3018685T3 (en) Method for the manufacture of a controlled release solid unit dosage form.
ES2010466A6 (es) Formas de administracion solidas, de rapida desintegracion.
HUP9801686A2 (hu) Amino-tetralin-származék alkalmazása kardiovaszkuláris megbetegedések terápiájában használható gyógyszer előállítására
ATE213933T1 (de) Orale zubereitung, enthaltend in einer in wässrigem medium quellbaren matrix wenigstens einen pharmazeutischen wirkstoff
KR930021206A (ko) 시타라빈 옥포스페이트 경질 캡슐제
UA50814C2 (uk) Анальгетичний лікарський засіб
DK0381182T3 (da) Erosionskontrolleret frigivelsessystem for aktive midler og fremgangsmåde til fremstilling deraf
RU2000111645A (ru) Способ лечения геморрагической лихорадки с почечным синдромом
MX9706361A (es) Sales de carboxiamidas estables, de accion prolongada, composiciones que las contienen y el uso de las mismas.
BG103023A (en) Bronchodilatation medicamentous form

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117319

Country of ref document: FI

MM Patent lapsed